A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma

NCT04434469 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Interventions

DRUG: RO7297089

Sponsor

Genentech, Inc.